Table 4.
Frequency of Individual Drugs in the Baseline Treatment Regimen at Time of Initiation of Bedaquiline or Delamanid in the endTB Observational Study Cohort, 1 April 2015–30 June 2018a
| Drugs Comprising the Baseline Treatment Regimen | n (%) |
|---|---|
| Bedaquiline | 1630 (71.0) |
| Delamanid | 904 (39.4) |
| Bedaquiline and delamanid | 238 (10.4) |
| Linezolid | 1826 (79.5) |
| Clofazimine | 1606 (69.9) |
| Cycloserine | 1520 (66.2) |
| Moxifloxacin or levofloxacin | 1456 (63.4) |
| Prothionamide/Ethionamide | 1015 (44.2) |
| Kanamycin, capreomycin, or amikacin | 925 (40.3) |
| P-aminosalicylic acid | 619 (27.0) |
| Imipenem/Cilastatin or meropenem | 376 (16.4) |
| Pyrazinamide | 1338 (58.3) |
| Median number of drugs included in baseline regimen (IQR) | 6 (5–6) |
| Median number of likely effective drugs included in baseline regimen (IQR)b | 5 (4–5) |
| Number with bedaquiline or delamanid and at least 1 QT prolonging drugsc | 2197 (95.7) |
Abbreviation: IQR, interquartile range.
(N = 2296).
Likely effective drugs were either drugs for which all reported testing (genotypic or phenotypic) showed drug susceptibility (for those drugs with reliable testing, ie, fluoroquinolones, amikacin, kanamycin and capreomycin) or drugs with no resistance reported and that the patient had not previously received for more than 1 month.
QT prolonging drugs: levofloxacin, moxifloxacin, or clofazimine.